FDA Approves BREYANZI®, First CAR-T Cell Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
FDA Approves TEVIMBRA® for Advanced Esophageal Squamous Cell Carcinoma
Circulating Tumor DNA Can be Used as an Early Marker of Immunotherapy Response
Late Breaking Abstract – 2024 ASCO GU Cancers Symposium: Adjuvant KEYTRUDA® Improves Overall Survival in Renal cell Carcinoma
Late Breaking Abstract – 2024 ASCO GU Cancers Symposium: Subcutaneous Nivolumab Offers Efficiency and Efficacy in Renal Cell Carcinoma
FDA Approves KEYTRUDA® with Chemotherapy for HER2-Negative Gastric or GE Junction Adenocarcinoma
FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer
Late Breaking Abstract – ESMO Congress 2023: Perioperative OPDIVO® Plus Chemotherapy Improves Survival in Resectable Non Small Cell Lung Cancer
FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma
KEYTRUDA® in Combination with HER2 Blockade Improves PFS in Gastric and GE Junction Cancer
FDA Approves Perioperative KEYTRUDA® for Resectable Early Stage Non Small Cell Lung Cancer
Adjuvant KEYTRUDA® in Resected NSCLC Irrespective of PD-L1 Expression
Late Breaking Abstract- ASCO 2023: BCMA-directed CAR T-cell therapy Cilta-cel in Lenalidomide Refractory Multiple Myeloma
Perioperative Pembrolizumab for Early Stage Non Small Cell Lung Cancer
Pembrolizumab Plus Chemotherapy Improves Overall Survival in Advanced Biliary Tract Cancer
Personalized mRNA Cancer Vaccine in Combination with KEYTRUDA® Improves Relapse Free Survival in Resected High Risk Melanoma
FDA Approves Enfortumab vedotin with Pembrolizumab for Advanced Urothelial Carcinoma
Tremelimumab in Combination with Durvalumab and Chemotherapy in Metastatic Non Small Cell Lung Cancer: The Phase III POSEIDON Study
Real World Experience of Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma
Zolbetuximab Plus Chemotherapy Improves Survival in CLDN18.2 Positive Metastatic Gastric and Gastroesophageal Junction Cancer
Bottom Ad
Advertisement
Subscribe
